Being able to personalize a patient's treatment is one of the cornerstones of nuclear medicine, but how are we able to do that? PET-Guided radiotherapy is one answer. In addition to staging and defining a disease, PET imaging can also give providers important information about what's going on in the body while a patient is undergoing their treatment regimen. PET can be used to adjust radiotherapy based on changes in the body and disease progression — whether higher doses are needed in areas with more aggressive cancer, or lower, but still effective, doses can be administered to ensure the minimal amount of toxicity to a patient. Join us for this episode of the JNM Podcast as host Ken Herrmann talks with radiotherapy experts Wolfgang Fendler and Nancy Lee. Listen on YouTube or wherever you stream podcasts.

This episode is sponsored by GE Healthcare: https://www.gehealthcare.com/products/molecular-imaging

Biomarkers: what are they and how are they useful in the diagnosis and treatment of prostate cancer? On this episode of the JNM Podcast, our panel of experts explores what they call a "liquid biopsy:" using biomarkers shed by cancer cells into the bloodstream to gain vital insights about the disease and its progression, identify candidates who would benefit from certain therapies, and monitor the effectiveness of treatments. Listen now to learn more about the clinical use of biomarkers. Our host Ken Herrmann, MD, is joined by Jake Berchuck, MD, Alexander Wyatt, PhD, and Rana McKay, MD.

This episode is sponsored by Precede Biosciences: https://www.precede.bio/

Is it really happening? Astatine-211 is a promising new radionuclide being further developed and researched for the treatment of cancer. It is a short half-life alpha-emitter that's attracting more interest from the nuclear medicine community as investors take notice of its potential and production capacity improves. So where will 211At be by 2030? And is this a radionuclide that could show up in a clinical setting in the near future? Join host Ken Herrmann, MD with guests Brenda Sandmaier, MD, Tadashi Watabe, MD, and Ferid Haddad PhD, as they discuss the future of this isotope.

This episode is sponsored by IBA Radiopharma Solutions (https://www.iba-radiopharmasolutions.com/) and Accelerate.eu (https://ihi-accelerate.eu/)

In this live episode of The JNM Podcast, Johannes Czernin interviews Anna Karmann to talk about the various career trajectories available in nuclear medicine.

The JNM Podcast is back and live from New Orleans. Guests David Mankoff, Hossein Jadvar, and Todd Peterson answer the question: "Can society-based journals compete with corporate-based publications?"

You love the column, now hear it in person! Throughout the meeting, JNM Editor in Chief Johannes Czernin will host Discussions with Leaders to talk about the most important and exciting topics in nuclear medicine. First up is Richard Wahl, MD.

Standardized uptake values (SUV) measure a patient's response to nuclear medicine therapy. But what other markers of success are there, and do these markers and the interpretation of them vary depending on the disease being imaged? Sally Barrington, MD, works specifically on lymphoma and shares her expertise on what markers of success and criteria are critical to her in understanding patients' responses to treatment.  Joining her, along with our host Ken Herrmann, MD, are Louise Emmett, MD, and Irene Buvat, PhD. The panel also discusses the role of AI tools in analyzing risk and response assessment in lymphoma. Tune in now!

Below are resources provided by Dr. Barrington: 

Tool to measure the international metabolic prognostic index 'IMPI':https://petralymphoma.org/impi/

Benchmark dataset for MTV measurement:   https://zenodo.org/records/11409717

For more JNM articles on this topic, see below:

Methodology for MTV described in DOI: https://jnm.snmjournals.org/content/early/2020/07/16/jnumed.119.238923

Is 18F-FDG Metabolic Tumor Volume in Lymphoma Really Happening? https://doi.org/10.2967/jnumed.123.267022

Deep learning enables TMTV estimation  https://doi.org/10.2967/jnumed.120.242412

This episode is sponsored by SOFIE Biosciences: https://sofie.com/

Is PSMA becoming so regularly used that it's...boring? Not according to this lively discussion. Join us for episode 9 of the JNM Podcast, where host Ken Herrmann discusses the state of PSMA PET with experts Thomas Hope, Oliver Sartor, and Wolfgang Fendler. The panel talks about PSMA PET in clinical trials vs. real-life disease management, appropriate use criteria and its evolution, and patient and treatment data. Plus, what's next for PSMA as it matures into adulthood? Tune in to find out!

Thanks to Sofie Biosciences for sponsoring this episode. https://sofie.com/

The JNM Podcast is back in 2025! Join Ken Herrmann, MD, and co-moderator Frank Bengel, MD, for an episode on cardiovascular perfusion imaging. In the U.S., SPECT imaging makes up five to six million studies per year. But PET studies make up just 2.2 million, and only 7%, or 150,000 of those, are cardiac PET imaging. But that may be about to change. The FDA has recently approved Flurpiridaz F-18, which may make cardiac imaging more accessible to patients across the country. Here to discuss the utility of the F-18 label and the future of myocardial perfusion imaging are Jamshid Maddahi, MD, FACC, FASNC, and Sharmila Dorbala, MD, MPH.

Thanks to GE Healthcare for sponsoring this episode! https://www.gehealthcare.com/products/molecular-imaging-agents/flyrcado

Get ready for an episode that's a bit...meta. In Episode 7, our host Ken Herrmann is joined by the podcasters behind GU Cast: Declan Murphy, FRACS, FRCS, and Renu Eapen, MBBS, FRACS. Together with Wolfgang Weber, MD, PhD, they discuss how social media has shaped the landscape of medicine - from how we get medical news, to sharing new research to interacting with colleagues and patients. Tune in now!

Thanks to Sofie Biosciences for sponsoring this episode! https://sofie.com/